What does the evidence say? When Canada's health care decision-makers need to know, they ask CADTH. We're a trusted source for evidence on drugs and medical devices. How can we help you with your next decision?
Tisagenlecleucel (Kymriah) for Pediatric Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma Tisagenlecleucel is a chimeric antigen receptor (CAR) T-cell therapy for the treatment of adults with relapsed or refractory diffuse larg... Published on: January 15, 2019
Detection and Diagnosis of Sepsis in Rural and Remote Areas: An Environmental Scan CADTH undertook an Environmental Scan to understand current practices for detecting and diagnosing sepsis in remote and rural health care... Published on: January 9, 2019
Access to and Availability of Non-Pharmacological Treatments for Chronic Non-Cancer Pain in Canada: An Environmental Scan CADTH conducted an Environmental Scan to understand the current context around access to and the availability of non-pharmacological trea... Published on: November 21, 2018
2019 CADTH Symposium CADTH will be hosting its annual Symposium at the Shaw Centre in Edmonton, Alberta, from April 14 to 16, 2019. For more information, plea... Event Date: April 14, 2019 - April 16, 2019
New Opportunity: Parallel Scientific Advice From CADTH and NICE CADTH is pleased to announce a new collaboration with England’s NICE (National Institute for Health and Care Excellence) to offer paralle... Published on: February 6, 2019
Nominations now open for Patient and Community Advisory Committee CADTH is currently seeking individuals with diverse experiences with the Canadian health care system for our Patient and Community Adviso... Published on: January 28, 2019
Call for Patient Input and Clinical Experts: Kynmobi CADTH has received the following notice(s) of pending drug submission(s). Brand name Kynmobi Generic name apomorphine hydrochloride Manu... Published on: January 25, 2019
